storage stability is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
=== Decay series / coupled decay === In nuclear science and pharmacokinetics, the agent of interest might be situated in a decay chain, where the accumulation is governed by exponential decay of a source agent, while the agent of interest itself decays by means of an exponential process. These systems are solved using the Bateman equation. In the pharmacology setting, some ingested substances might be absorbed into the body by a process reasonably modeled as exponential decay, or might be deliberately formulated to have such a release profile.
Certain progestins, namely cyproterone acetate and medroxyprogesterone acetate and as described previously, are used at high doses as functional antiandrogens due to their antigonadotropic effects to help suppress testosterone levels in transgender women. Aside from the specific use of testosterone suppression however, there are no other indications of progestogens in transgender women at present. In relation to this, the use of progestogens in transgender women is controversial, and they are not otherwise routinely prescribed or recommended. Besides progesterone, cyproterone acetate, and medroxyprogesterone acetate, other progestogens that have been reported to have been used in transgender women include hydroxyprogesterone caproate, dydrogesterone, norethisterone acetate, and drospirenone. Progestins in general largely have the same progestogenic effects however, and in theory, any progestin could be used in transgender women. Clinical research on the use of progestogens in transgender women is very limited. Some patients and clinicians believe, on the basis of anecdotal and subjective claims, that progestogens may provide benefits such as improved breast and/or nipple development, mood, and libido in transgender women. There are no clinical studies to support such reports at present. No clinical study has assessed the use of progesterone in transgender women, and only a couple of studies have compared the use of progestins (specifically cyproterone acetate and medroxyprogesterone acetate) versus the use of no progestogen in transgender women.
Bromley is a large town in Greater London, England, within the London Borough of Bromley. It is 9+1⁄2 miles (15 kilometres) southeast of Charing Cross, and had an estimated population of 97,540 as of 2021. Originally part of Kent, Bromley became a market town, chartered in 1158. Its location on a coaching route and the opening of a railway station in 1858 were key to its development and the shift from an agrarian village to an urban town. As part of the growth of London's conurbation in the 20th century, Bromley Town significantly increased in population and was incorporated as a municipal borough in 1903 and became part of the London Borough of Bromley in 1965. Bromley today forms a major retail and commercial centre. It is identified in the London Plan as one of the 13 metropolitan centres of Greater London.
=== Hypersensitivity === Hypersensitivity is a rarely described but significant complication of parenteral nutrition therapy. First reported in 1965, the incidence of these reactions is speculated to be around one in 1.5 million patients who are provided parenteral nutrition. There is a wide range in how and when these reactions manifest. Cutaneous manifestations are the most common presentation. Hypersensitivity is thought to occur to the individual components of TPN, with the intravenous lipid emulsion being the most frequently implicated component, followed by the multivitamin solution and the amino acid solution. Medications Patients who are receiving intravenous parenteral nutrition may also need to receive intravenous medications as well using the same Y-site. It is important to assess the compatibility of the medications with the nutrition components. Incompatibilities can be observed physically through discoloration, phase separation, or precipitation.
Sources: en.wikipedia.org
The territory of the Viceroyalty of New Granada became the Republic of Colombia, organized as a union of the current territories of Colombia, Panama, Ecuador, Venezuela, parts of Guyana and Brazil and north of Marañón River. The Congress of Cúcuta in 1821 adopted a constitution for the new Republic. Simón Bolívar became the first President of Colombia, and Francisco de Paula Santander was made Vice President. However, the new republic was unstable and the Gran Colombia ultimately collapsed. Modern Colombia comes from one of the countries that emerged after the dissolution of Gran Colombia, the other two being Ecuador and Venezuela. Colombia was the first constitutional government in South America, and the Liberal and Conservative parties, founded in 1848 and 1849, respectively, are two of the oldest surviving political parties in the Americas. Slavery was abolished in the country in 1851. Internal political and territorial divisions led to the dissolution of Gran Colombia in 1830. The so-called "Department of Cundinamarca" adopted the name "New Granada", which it kept until 1858 when it became the "Confederación Granadina" (Granadine Confederation). After a two-year civil war in 1863, the United States of Colombia was created, which became known as the Republic of Colombia in 1886.
=== Period 3: final narrative evolution === The final stage at Kizil is Period 3 of the Second Indo-Iranian Style. Towards the end of its florescence, Kizil saw the emergence of the domed central pillar cave, a type of "central pillar" structure, with niche and circumambulating corridor, but with a very uncharacteristic near-cubic main cella crowned by a magnificent cupola decorated with divinities. The style of painting is very refined, and can also be seen in some other caves in the region such as in Kumtura. The iconography too has evolved, with a cosmological Buddha becoming omnipresent and majestic, often surrounded by myriads of emanations of smaller Buddhas. This exceptional and very refined type of cave is exemplified by Cave 123, the "Cave with the Ring-Bearing Doves". It represents a final narrative evolution, in which the figures of the cosmological Buddha predominate, while secondary figures and stories take an ever-smaller role.
The first act of the Continental Congress in favor of what later came to be called whistleblowing came in the 1777-8 case of Samuel Shaw and Richard Marven. The two seamen accused Commander in Chief of the Continental Navy Esek Hopkins of torturing British prisoners of war. The Congress dismissed Hopkins and then agreed to cover the defense cost of the pair after Hopkins filed a libel suit against them under which they were imprisoned. Shaw and Marven were subsequently cleared in a jury trial. To be considered a whistleblower in the United States, most federal whistleblower statutes require that federal employees have reason to believe their employer violated some law, rule, or regulation; testify in or commence a legal proceeding on the legally protected matter; or refuse to violate the law. In cases where whistleblowing on a specified topic is protected by statute, U.S. courts have generally held that such whistleblowers are protected from retaliation. However, a closely divided U.S. Supreme Court decision, Garcetti v. Ceballos (2006) held that the First Amendment free speech guarantees for government employees do not protect disclosures made within the scope of the employees' duties. In the United States, legal protections vary according to the subject matter of the whistleblowing and sometimes the state where the case arises. In passing the 2002 Sarbanes–Oxley Act, the Senate Judiciary Committee found that whistleblower protections were dependent on the "patchwork and vagaries" of varying state statutes.
Sources: en.wikipedia.org
The main use for 4-aminosalicylic acid is for the treatment of tuberculosis infections. In the United States, 4-aminosalicylic acid is indicated for the treatment of tuberculosis in combination with other active agents. In the European Union, it is used in combination with other medicines to treat adults and children from 28 days of age who have multi-drug resistant tuberculosis when combinations without this medicine cannot be used, either because the disease is resistant to them or because of their side effects.
Initially, by analogy with neutron magic number 126, the next proton shell was also expected at element 126, too far beyond the synthesis capabilities of the mid-20th century to get much theoretical attention. In 1966, new values for the potential and spin–orbit interaction in this region of the periodic table contradicted this and predicted that the next proton shell would instead be at element 114, and that nuclei in this region would be relatively stable against spontaneous fission. The expected closed neutron shells in this region were at neutron number 184 or 196, making 298Fl and 310Fl candidates for being doubly magic. 1972 estimates predicted a half-life of around 1 year for 298Fl, which was expected to be near an island of stability centered near 294Ds (with a half-life around 1010 years, comparable to 232Th). After making the first isotopes of elements 112–118 at the turn of the 21st century, it was found that these neutron-deficient isotopes were stabilized against fission. In 2008 it was thus hypothesized that the stabilization against fission of these nuclides was due to their oblate nuclei, and that a region of oblate nuclei was centred on 288Fl. Also, new theoretical models showed that the expected energy gap between the proton orbitals 2f7/2 (filled at element 114) and 2f5/2 (filled at element 120) was smaller than expected, so element 114 no longer appeared to be a stable spherical closed nuclear shell.
== Guest characters == Fragrantian Erika (フラグラント星人 衛里香, Furanguranto Seijin Erika): The princess of a royal intergalactic family from Planet Fragrant. She is kidnapped by Kevakia, who attempts to ransom her for the rare-but-powerful Wellness Stone, but she is rescued by Ban and Hoji, who delete Kevakia. Erika is portrayed by Risa Yoshiki (吉木 りさ, Yoshiki Risa). Doltockian Mano Mark (ドルトック星人マノ・マーク, Dorutokku Seijin Mano Māku): A scientist from Planet Doltock who attempts to deal with Beildon under the alias of Iwaki (岩木), only to be arrested for abetting the Alienizer's crimes. His human form is portrayed by Minosuke (みのすけ). Juuzaian Braidy (ジューザ星人ブライディ, Jūza Seijin Buraidi): A mantis-themed alien from Planet Juuza whom Kersus framed for the murder of her sister Karmia and Agent Abrella enlarged to distract the Dekarangers, who discover the truth and arrest Braidy for causing property damage in his enlarged state. Braidy is voiced by Yūsuke Numata (沼田 祐介, Numata Yūsuke). Hikaru Hiwatari (日渡 氷狩, Hiwatari Hikaru): A young ESPer with the ability to teleport inanimate objects. Originally a street wanderer, he hated humans because they mistreated him due to his powers, and he wanted to leave the planet as soon as possible. An Alienizer named Dazgonelr uses this to manipulate Hikaru into helping him commit crimes, until Jasmine convinces Hikaru to trust her. Following Dazgonelr's deletion, Hikaru leaves Earth to join S.P.D.'s training academy.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.